# Research Pulse — 2026-09-18 _Generated 2026-09-18 07:30 KST · AI × Bioresearch Daily synthesis_ Brown Biotech daily research pulse — multi-front synthesis across CRISPR / gene editing, AI drug discovery, protein AI, single-cell foundation models, FDA/regulatory, and spatial transcriptomics. Sources: company filings, peer-reviewed journals, FDA guidance, conference disclosures. --- ### Post 1: 오늘의 전체 흐름 🧬 **AI × Bioresearch Daily — 9월 18일 (금요일) · Industrializing(산업화) Day** 9/18(산업화) → 9/17(확산) → 9/16(종합) → 9/15(검증) → 9/14(정밀화) → 9/13(가동화) → 9/12(다속화) → 9/11(전이). Scaling(9/17)된 기술들이 **실제 FDA 규제 프레임워크 구체화·빅파마 AI 투자 집중·단일세포 멀티모달 FDAL Multimodal FDAL 산업 생태계 형성(Industrializing) 단계로 이전하며 규제 표준화와 산업 거버넌스가 동시에 가속화되는 날** — Feierman et al.으로 FDA 2026-02 plausible mechanism framework 발표 + prime editing urea cycle disorders 7개 Ultra-rare diseases umbrella clinical trial 발표(American Journal of Human Genetics 2026), Lin et al.으로 2026년 빅파마 AI 플래트폰 Deals 급증 — Eli Lilly/Recursion/Regor/Novartis/AbbVie/Genentech 다수 대형 계약 (GEN Biotechnology 2026), Boya Ji et al.으로 CAPTAIN multimodal foundation model — scRNA + surface protein 382종 co-assay 4M cells 통합 학습 + zero-shot protein imputation + batch harmonization (Nature Communications 2026), Nguyen et al.으로 spatial omics TME profiling — ST/SP 통합 + AI/ML cross-platform integration + precision cancer medicine (Clinical & Translational Immunology 2026), Li et al.으로 12개 암종 373 samples 56 LCPs + Niche_4 poor prognosis + Niche_11 better survival (Cell Reports Medicine 2026), Ji et al.으로 prime editing neuropsychiatric disorders — BBB penetration + split-AAV/engineered peptides突破 + 신경퇴행성 질환 적용 (Neuroprotection 2026)이 동시에 진행된다. Industrializing은 Scaling의 산업 생태계 형성 단계다. 규제 프레임워크 구체화와 빅파마 투자 집중으로 기술에서 산업으로의 전환이 가속화되며, 통합 멀티모달 FDAL과 공간적 종양 미세환경 분석이 임상 적용 가능성을 실증하는 날이다. *출처: [Feierman FDA Plausible Mechanism AJHG 2026](https://consensus.app/papers/details/c10e0f99f20b517e8bb3b5ae4b666dcc/), [Lin Pharma AI 2026 Deals GEN Biotechnology 2026](https://consensus.app/papers/details/bc6e9ea3ec2e5025af707131d2fa0ca7/), [Boya Ji CAPTAIN Multimodal FM Nature Communications 2026](https://consensus.app/papers/details/40361e55d4815c1dae3d5f6a95d4468a/), [Nguyen Spatial Omics TME Clinical & Translational Immunology 2026](https://consensus.app/papers/details/1b906e5abaaf5e789aaabde458127265/), [Li Pan-cancer Spatial Transcriptomics Cell Reports Medicine 2026](https://consensus.app/papers/details/f420ab985e1257e18352cac9e0c425cf/), [Ji Prime Editing Neuropsychiatric Neuroprotection 2026](https://consensus.app/papers/details/6f2f6891edcd524b9e54932910f51d1d/)* *#IndustrializingDay #Feierman #AmericanJournalOfHumanGenetics #FDA #PlausibleMechanism #PrimeEditing #UreaCycleDisorders #UltraRare #UmbrellaTrial #Lin #GENBiotechnology #PharmaAI #BigPharma #2026Deals #EliLilly #Novartis #AbbVie #Genentech #Recursion #Regor #BoyaJi #CAPTAIN #NatureCommunications #Multimodal #FoundationModel #scRNA #Protein #ZeroShot #Imputation #Nguyen #ClinicalTranslationalImmunology #SpatialOmics #TME #PrecisionCancer #Li #CellReportsMedicine #PanCancer #LCP #Niche4 #Niche11 #Ji #Neuroprotection #BBB #Neuropsychiatric #PrimeEditing #Scaling #Industrializing #RegulatoryFramework #BiomedicalAI #DailyReport* --- ### Post 2: FDA/규제 — FDA 2026 Plausible Mechanism Framework + Prime Editing Umbrella-of-Umbrellas Clinical Trial 📋 **[FDA/규제] Feierman et al.으로 FDA 2026-02 plausible mechanism framework 발표 + prime editing urea cycle disorders 7개 UCDs umbrella-of-umbrellas clinical trial 공식 논의(American Journal of Human Genetics 2026) + Oo et al.으로 FDA 38 CGTs 86.8% orphan + 92.1% expedited + 73.7% 단일 pivotal study + 17.9% postmarketing primary efficacy (J Clinical Pharmacology 2026): FDA 규제 프레임워크 구체화와 Gene Therapy 산업화 동시 확인** FDA 규제 체계의**구체화와 Gene Therapy 산업화(Industrializing)**가 출처에서 동시에 확인된다[1][2]. **FDA 2026 Plausible Mechanism Framework + PE Umbrella-of-Umbrellas Trial[1]** E. Feierman et al.(American Journal of Human Genetics 2026)의 연구는 FDA 2026-02 제시된 plausible mechanism framework의 첫 공식 임상 시험 적용을 보고한다. **FDA 2026-02 Framework**: ultra-rare genetic diseases을 위한 맞춤화 prime editing platform 개발·승인과 관련된 규제 프레임워크. **적용 대상 — 7개 UCDs**: urea cycle disorders 7개 질환 —uru cycle disorders (UCDs)는 간에서 독소 배출을 담당하는 효소 경로의 유전적 결함. **Umbrella-of-umbrellas trial 개념**: 7개 UCDs를 단일 umbrella trial로 통합 — 환자들의 개별 유전적 돌연변이에 맞는 prime editing 치료를 같은 임상 프레임워크에서 테스트. **FDA 공식 회의 결과**: umbrella-of-umbrellas trial에 대한 FDA 공식 meeting 완료. **적용 가능성 확대**: other liver-centered ultra-rare disorders로 확대 가능. **핵심**: FDA plausible mechanism framework + PE umbrella-of-umbrellas trial — FDA 규제 구체화 + Gene therapy Industrializing Consolidating. **FDA CGTs 규제 현황: 38개 승인 86.8% Orphan + 17.9% Postmarketing Efficacy[2]** C. Oo et al.(The Journal of Clinical Pharmacology 2026)의 연구는 FDA gene therapy approvals의 현황을 분석한다[2]. **총 38개 CGTs 승인**(2025-12-31 기준). **Orphan designation**: 86.8% (33개). **Expedited pathway**: 92.1% (35개). **단일 pivotal study**: 73.7% (28개). **Postmarketing requirements**: 73.4% (28개), 총 52개 후속 연구. **Postmarketing primary efficacy endpoint**: 17.9%만 포함. **FDA Platform Initiatives**: plausible mechanism framework, CMC flexibility initiative, advanced manufacturing technologies program. **핵심**: FDA CGTs 38개 승인 현황 + postmarketing efficacy 17.9% 한계 — gene therapy Industrializing Consolidating. **9월 17일 Scaling vs 오늘의 차별점**: 9/17이 **Shahzad FDA 38 CGTs assessment**으로 **postmarketing efficacy 17.9% 한계**(Scaling)를 제시했다면, 오늘은 **Feierman AJHG**으로 **FDA 2026-02 plausible mechanism framework 공식 발표 + umbrella-of-umbrellas trial FDA 공식 회의 완료**(Industrializing — 규제 구체화里程碑)를(new angle), **Oo FDA 38 CGTs 현황**을 **Industrializing 문맥에서 재해석**(regulatory foundation)으로 재제시한다. Scaling(9/17) → FDA/규제 Industrializing(9/18). 실무 함의: 규제 전략팀에서 Feierman et al.의 plausible mechanism framework를 참조하여 ultra-rare disease gene therapy regulatory strategy를 수립해야 한다. *출처: [Feierman FDA Plausible Mechanism AJHG 2026](https://consensus.app/papers/details/c10e0f99f20b517e8bb3b5ae4b666dcc/), [Oo FDA Gene Therapy Approvals J Clinical Pharmacology 2026](https://consensus.app/papers/details/181658e93c825ea581a0664845a98d12/)* *#FDA #GeneTherapy #Regulation #Feierman #AmericanJournalOfHumanGenetics #PlausibleMechanism #Framework #PrimeEditing #UmbrellaTrial #UCDs #UreaCycleDisorders #UltraRare #RareDisease #2026 #CMC #AdvancedManufacturing #PlatformTechnology #Oo #JClinicalPharmacology #38Approvals #OrphanDesignation #ExpeditedPathway #Postmarketing #Efficacy #IndustrializingDay #RegulatoryFramework #RegulatoryScience #GeneTherapy #Approval #BiomedicalAI #DailyReport* --- ### Post 3: CRISPR & Gene Editing — Prime Editing Neuropsychiatric Applications + BBB Penetration Breakthrough 🪄 **[CRISPR/Gene Editing] Ji et al.으로 prime editing neuropsychiatric disorders — BBB penetration + split-AAV systems + lipid nanoparticles + engineered peptides突破 + 신경퇴행성 질환 적용 가능성(Neuroprotection 2026) + Lushington et al.으로 PE first-in-human functional restoration + promising safety profile(Molecular Therapy 2026) + Feierman et al.으로 FDA plausible mechanism framework umbrella-of-umbrellas trial (American Journal of Human Genetics 2026): CRISPR Industrializing(산업화) 동시 확인** CRISPR 유전자 편집 기술의**신경계 질환 적용 확대와 규제 프레임워크 산업화(Industrializing)**가 출처에서 동시에 확인된다[3][1]. **Prime Editing Neuropsychiatric Disorders: BBB Penetration Breakthrough[3]** T. Ji et al.(Neuroprotection 2026)의 review는 prime editing의 신경계 질환 적용을 분석한다. **PE 매력**: precise base substitutions, small insertions, deletions + double-strand breaks 없음. **BBB penetration 전략 3가지**: (i) split-AAV systems — 적당한 크기로 분할하여 AAV 전달 용량 해결, (ii) lipid nanoparticles — 표적화된 전달 시스템, (iii) engineered peptides — BBB 통과 능력이 향상된 펩타이드. **적용 가능 질환**: monogenic neurodevelopmental disorders — Rett syndrome, Fragile X syndrome, Dravet syndrome 등. **핵심 성과 1 — In vitro/in vivo 모두 proof-of-concept 확인**: 기능적 회복 및 기능적 구호 실증. **핵심 성과 2 — Blood-brain barrier penetration 전략**: engineered peptides, AAV capsid engineering, nanoparticle delivery. **핵심 성과 3 — Comprehensive genome-wide safety evaluations 필요성**: 장기적 안전성 평가. **핵심**: PE neuropsychiatric disorders + BBB penetration breakthrough — CRISPR Industrializing Consolidating. **PE First-in-Human: Functional Restoration + Promising Safety Profile[1]** C. Lushington et al.(Molecular Therapy 2026)의 review는 prime editing의 first-in-human study 결과를 분석한다[1]. **Functional restoration 확인 + promising safety profile**. **핵심**: PE first-in-human functional restoration — CRISPR Industrializing Consolidating. **FDA Plausible Mechanism Framework + PE Umbrella-of-Umbrellas Trial[1]** E. Feierman et al.(American Journal of Human Genetics 2026)의 연구는 FDA 2026-02 framework 적용을 보고한다[1]. **핵심**: FDA framework + umbrella trial — CRISPR Industrializing Consolidating. **9월 17일 Scaling vs 오늘의 차별점**: 9/17이 **Lushington PE first-in-human**으로 **실제 인체 실험 기능적 회복 + 안전한 프로파일**(Scaling)을, **Yu PE7/PE8 evolution**으로 **architecture innovations를 통한 효율성 향상**(Scaling)을 제시했다면, 오늘은 **Ji Neuroprotection**으로 **BBB penetration breakthrough + split-AAV/lipid nanoparticles/engineered peptides 3가지 전략**(Industrializing — 신경계 질환 산업화突破口)를(new angle), **Feierman AJHG**으로 **FDA plausible mechanism framework umbrella-of-umbrellas trial 공식 회의 완료**(Industrializing — 규제 산업화)를 동시에 제시한다. Scaling(9/17) → CRISPR Industrializing(9/18). 실무 함의: 신경과 gene therapy 개발팀에서 Ji et al.의 BBB penetration strategy를 참조하여 CNS-directed PE therapeutic strategy를 수립해야 한다. *출처: [Ji Prime Editing Neuropsychiatric Neuroprotection 2026](https://consensus.app/papers/details/6f2f6891edcd524b9e54932910f51d1d/), [Lushington PE First-in-Human Molecular Therapy 2026](https://consensus.app/papers/details/79a173589b1d58598fd94fa334768881/), [Feierman FDA Plausible Mechanism AJHG 2026](https://consensus.app/papers/details/c10e0f99f20b517e8bb3b5ae4b666dcc/)* *#CRISPR #GeneEditing #Ji #Neuroprotection #PrimeEditing #Neuropsychiatric #BBB #BloodBrainBarrier #SplitAAV #LNP #EngineeredPeptides #RettSyndrome #FragileX #DravetSyndrome #Lushington #MolecularTherapy #FirstInHuman #FunctionalRestoration #SafetyProfile #Feierman #AmericanJournalOfHumanGenetics #FDA #PlausibleMechanism #UmbrellaTrial #UCDs #IndustrializingDay #CNS #Neurodegenerative #GeneTherapy #BBBpenetration #Delivery #BiomedicalAI #DailyReport* --- ### Post 4: AI 신약 — 2026년 빅파마 AI Deals 급증 + Multi-Omics AI Drug Discovery 산업 생태계 💊 **[AI 신약] Lin et al.으로 2026년 Eli Lilly/Recursion/Regor/Novartis/AbbVie/Genentech 등 빅파마 AI 플래트폰 Deals 급증 — 생성형 AI + 단백질 설계 + 합성 데이터 + 약물 재창출 전领域 거래 확대(GEN Biotechnology 2026) + Liu et al.으로 multi-omics + AI 통합 약물 발견 — GWAS·transcriptomics·proteomics·metabolomics + deep learning + 표적 식별·lead 최적화·임상 시험 설계(Signal Transduction Targeted Therapy 2026) + Seyhan et al.으로 AI Phase II 한계 + FDA AI-enabled devices 승인 다수 + AI-discovered 후보물질 임상 진행 중(Critical Reviews Oncology Hematology 2026): AI drug discovery Industrializing(산업화) 동시 확인** AI-Driven Drug Discovery의**빅파마 투자 집중과 산업 생태계 형성(Industrializing)**이 출처에서 동시에 확인된다[4][5][6]. **2026년 빅파마 AI Deals 급증: Flurry of 2026 Deals[4]** F. Lin et al.(GEN Biotechnology 2026)의 기사는 2026년 빅파마 AI 플래트폰 Deals 급증세를 보고한다. **핵심 동향 — 2026년 대형 거래**: Eli Lilly + Recursion Pharmaceuticals, Regor Therapeutics + Novartis, AbbVie + Genentech 등 다수 대형 계약. **적용 분야**: (i) 생성형 AI — novel molecule generation, (ii) 단백질 설계 — structure-based design, (iii) 합성 데이터 — synthetic data generation, (iv) 약물 재창출 — drug repurposing. **핵심 메시지**: 빅파마들의 AI 플랫폼 투자 급증 — 2026년 업계 전체 거래 확대 확인. **핵심**: 2026년 빅파마 AI deals 급증 — AI drug discovery Industrializing Consolidating. **Multi-Omics + AI 통합 약물 발견: 전pipeline 적용[5]** Y. Liu et al.(Signal Transduction and Targeted Therapy 2026)의 review는 multi-omics와 AI 통합의 약물 발견 파이프라인 적용을 종합한다[5]. **Multi-omics 범위**: GWAS, transcriptomics, proteomics, metabolomics 통합. **핵심 성과 1 — AI 기반 표적 식별**: deep learning으로 복잡한 생물학적 데이터에서 표적 발견. **핵심 성과 2 — Lead 최적화**: AI-driven molecular optimization. **핵심 성과 3 — 임상 시험 설계**: precision trial design. **적용 분야**: oncology, neurodegenerative diseases, cardiovascular conditions. **AI 도구**: AlphaFold, MoleR, PocketCrafter, single-cell foundation models, LLMs. **핵심**: multi-omics + AI 통합 약물 발견 — AI drug discovery Industrializing Consolidating. **AI Drug Discovery Phase II 한계 + FDA AI Devices 승인 현황[6]** A. Seyhan et al.(Critical Reviews in Oncology/Hematology 2026)의 review는 AI drug discovery의 현황과 한계를 분석한다[6]. **FDA AI-enabled devices**: 다수 승인 — full AI-discovered drug은 아직 승인 없음. **핵심 성과 1 — AI-discovered 후보물질 임상 진행 중**: several AI-originated candidates in clinical development. **핵심 성과 2 — FDA AI devices**: numerous AI-enabled medical devices and software tools approved. **핵심 성과 3 — Translational impact**: AI의 임상적 영향력 확대 확인. **Challenges**: data quality, methodological limitations, regulatory/ethical frameworks 필요. **핵심**: AI drug discovery Phase II 한계 + AI-discovered 임상 진행 중 — AI drug discovery Industrializing Consolidating. **9월 17일 Scaling vs 오늘의 차별점**: 9/17이 **Jia Science DrugCLIP**으로 **10M× 속도 향상 + GenomeScreenDB**를(Scaling)을, **Singh Current Opinion**으로 **AlphaFold-ligand data gap**을(Scaling)을 제시했다면, 오늘은 **Lin GEN Biotechnology**으로 **2026년 Eli Lilly/Recursion/Regor/Novartis/AbbVie/Genentech 대형 Deals 급증**(Industrializing — 산업 투자集中)을(new angle), **Liu Signal Transduction**으로 **multi-omics + AI 통합 파이프라인 산업 적용**(Industrializing)을(new angle), **Seyhan review**를 **Industrializing 문맥에서 AI drug discovery 임상 현황 재확인**으로 재제시한다. Scaling(9/17) → AI drug discovery Industrializing(9/18). 실무 함의: 전략팀에서 Lin et al.의 2026년 Deals 동향을 참조하여 AI pharma partnership strategy를 수립해야 한다. *출처: [Lin Pharma AI 2026 Deals GEN Biotechnology 2026](https://consensus.app/papers/details/bc6e9ea3ec2e5025af707131d2fa0ca7/), [Liu Multi-Omics AI Signal Transduction Targeted Therapy 2026](https://consensus.app/papers/details/33ddb4ae99c05f869b6de8bd3c432a98/), [Seyhan AI Drug Discovery Critical Reviews Oncology Hematology 2026](https://consensus.app/papers/details/0e6b685fd2be56fb8a814115873a73d5/)* *#AI #DrugDiscovery #Lin #GENBiotechnology #PharmaAI #BigPharma #2026Deals #EliLilly #Recursion #Regor #Novartis #AbbVie #Genentech #GenerativeAI #ProteinDesign #SyntheticData #DrugRepurposing #Liu #SignalTransduction #TargetedTherapy #MultiOmics #GWAS #Transcriptomics #Proteomics #Metabolomics #DeepLearning #TargetIdentification #LeadOptimization #ClinicalTrial #Seyhan #CriticalReviews #Oncology #Hematology #FDA #AIDevices #PhaseII #IndustrializingDay #Investment #Partnership #Pipeline #BiomedicalAI #DailyReport* --- ### Post 5: 단백질 AI — AlphaFold Drug Discovery Applications + Protein-Ligand Data Gap 한계 체계화 🔬 **[단백질 AI] Singh et al.으로 AlphaFold-like models drug discovery에 protein-ligand data 필요성 — PSPMs 강점/한계 hierarchical framework + experimental/physics-based datasets 필요성(Current Opinion Structural Biology 2026) + Kinde et al.으로 AlphaFold drug discovery·disease mechanism·vaccine design applications — hybrid methods로 disorder/동적 구조 한계 극복(Results in Engineering 2026) + Yin et al.으로 ESMFold/RoseTTAFold/AlphaFold3 comprehensive review — drug discovery·enzyme engineering applications(Frontiers Molecular Biosciences 2026): 단백질 AI의 Industrializing(산업화) 한계와 적용 동시 확인** 단백질 AI의**약물 발견 적용 확대와 데이터 필요성(Industrializing)**이 출처에서 동시에 확인된다[7][8][9]. **AlphaFold-Like Models: Protein-Ligand Data Gap for Drug Discovery[7]** S. Singh et al.(Current Opinion in Structural Biology 2026)의 perspective는 PSPMs의 drug discovery 적용 한계를 분석한다[7]. **핵심 성과 1 — Hierarchical framework**: PSPMs의 drug discovery 강점/한계 체계적 분류. **핵심 성과 2 — PDB 50년 축적의 한계**: 실제 drug design 태스크를 위한 dataset 확대 필요. **핵심 성과 3 — Experimental + physics-based datasets 필요성**: challenging tasks를 위한 체계적 데이터셋 생성. **핵심**: AlphaFold-like models protein-ligand data gap — 단백질 AI Industrializing limitations. **AlphaFold Applications: Drug Discovery·Disease Mechanism·Vaccine Design[8]** M. Kinde et al.(Results in Engineering 2026)의 review는 AlphaFold의 다양한 적용 사례를 종합한다[8]. **핵심 성과 1 — Drug discovery acceleration**: 표적 식별에서 독성 예측까지. **핵심 성과 2 — Disease mechanism elucidation**: 질병 분자 기전 해석. **핵심 성과 3 — Vaccine design**: 병원체 단백질 구조 활용. **핵심 성과 4 — Hybrid methods로 disorder 극복**: 동적 구조 한계를 hybrid methods로 해결. **핵심**: AlphaFold drug discovery applications 종합 — 단백질 AI Industrializing Consolidating. **AlphaFold Comprehensive Review: ESMFold/RoseTTAFold/AlphaFold3[9]** T. Yin et al.(Frontiers in Molecular Biosciences 2026)의 review는 주요 단백질 구조 예측 모델을 종합한다[9]. **모델 비교**: ESMFold, RoseTTAFold, AlphaFold3. **적용 분야**: drug discovery, enzyme engineering, disease research. **Challenges**: disordered proteins, conformational changes, experimental integration. **핵심**: ESMFold/RoseTTAFold/AlphaFold3 comprehensive review — 단백질 AI Industrializing Consolidating. **9월 17일 Scaling vs 오늘의 차별점**: 9/17이 **Singh Current Opinion**으로 **AlphaFold-ligand data gap**을(Scaling)을, **Feldman AlphaFold3 adversarial**으로 **35% confidence reliability 한계**(Scaling)를 제시했다면, 오늘은 **Singh Current Opinion**을 **Industrializing 문맥에서 한계 체계화 프레임워크**로 재제시하고, **Kinde Results in Engineering**으로 **vaccine design 적용 확대**(Industrializing — 새로운 적용 영역)를(new angle), **Yin Frontiers**으로 **ESMFold/RoseTTAFold/AlphaFold3 산업 적용 종합**(Industrializing)을 동시에 제시한다. Scaling(9/17) → 단백질 AI Industrializing(9/18). 실무 함의: 단백질 설계팀에서 Singh et al.의 hierarchical framework를 참조하여 AlphaFold application strategy를 수립해야 한다. *출처: [Singh AlphaFold Protein Ligand Drug Discovery Current Opinion Structural Biology 2026](https://consensus.app/papers/details/81a3128ae1615cfeb1bd6544d3ad2f1b/), [Kinde AlphaFold Applications Results in Engineering 2026](https://consensus.app/papers/details/f459a7af7e615e27bfe6bd6e14625fea/), [Yin AlphaFold Comprehensive Review Frontiers Molecular Biosciences 2026](https://consensus.app/papers/details/880e72fce35255c4887811c76849c03a/)* *#AlphaFold #ProteinAI #Singh #CurrentOpinion #StructuralBiology #ProteinLigand #DataGap #PDB #HierarchicalFramework #Kinde #ResultsInEngineering #VaccineDesign #DiseaseMechanism #DrugDiscovery #AlphaFold2 #AlphaFold3 #Disorder #HybridMethods #Yin #FrontiersMolecularBiosciences #ESMFold #RoseTTAFold #ComprehensiveReview #EnzymeEngineering #IndustrializingDay #Applications #Limitations #DataNeeded #BiomedicalAI #DailyReport* --- ### Post 6: Single-Cell Multi-Omics FDAL — CAPTAIN Multimodal FDAL RNA+Protein 통합 + HiC-Foundation 3D Genome 🧮 **[Single-Cell Multi-Omics FDAL] Boya Ji et al.으로 CAPTAIN multimodal foundation model — scRNA + surface protein 382종 co-assay 4M cells 통합 학습 + zero-shot protein imputation + batch harmonization(Nature Communications 2026) + Wang et al.으로 SCMBench 23 methods 평가 — FMs이 DMs에 미달 + lightweight adaptation strategy 제안(Nature Communications 2026) + Wang X. et al.으로 HiC-Foundation Hi-C foundation model — cross-species 3D genome analysis + epigenomic activity prediction + single-cell Hi-C 적용(Nature Methods 2026): Single-Cell Multi-Omics FDAL Industrializing(산업화) 동시 확인** Single-Cell Multi-Omics FDAL의**멀티모달 통합과 산업 적용(Industrializing)**이 출처에서 동시에 확인된다[10][11][12]. **CAPTAIN: Multimodal FDAL RNA + Protein 통합[10]** B. Ji et al.(Nature Communications 2026)의 연구는 CAPTAIN multimodal foundation model을 제시한다. **핵심 혁신 — Multimodal 통합 학습**: scRNA + surface protein 382종을 동시에 학습. **Pre-training 규모**: 4M cells 이상. **핵심 성과 1 — Unified multimodal representations**: cross-modality dependencies 모델링. **핵심 성과 2 — Zero-shot protein imputation**:没见过的蛋白质的预测. **핵심 성과 3 — Batch harmonization**: 배치 효과 보정. **핵심 성과 4 — Fine-tuning + zero-shot 모두 우수**: downstream tasks에서 superior performance. **적용**: protein imputation/expansion, cell type annotation, batch harmonization, COVID-19 immune dynamics. **핵심**: CAPTAIN multimodal FDAL — RNA + protein 통합 + zero-shot — 단백질 AI Industrializing Consolidating. **SCMBench: Foundation Models가 Domain-Specific Models에 미달[11]** Y. Wang et al.(Nature Communications 2026)의 연구는 SCMBench로 23개 방법을 평가한다[11]. **핵심 성과 1 — FMs < DMs**: foundation models이 domain-specific models에 미달. **핵심 성과 2 — Lightweight adaptation strategy**: 성능 격차 해소를 위한 경량 adaptation 전략 제안. **핵심 성과 3 — Integration accuracy + biomarker detection + trajectory inference + batch effect correction**: 종합적 평가. **핵심**: SCMBench FMs < DMs + lightweight adaptation — Single-Cell FM Industrializing limitations. **HiC-Foundation: 3D Genome Foundation Model[12]** X. Wang et al.(Nature Methods 2026)의 연구는 HiC-Foundation foundation model을 제시한다[12]. **훈련 데이터**: massive Hi-C data. **핵심 성과 1 — Cross-species generalizability**: 다양한 종에서 일반화 가능. **핵심 성과 2 — 3D genome analysis**: chromatin structure 분석. **핵심 성과 3 — Epigenomic activity prediction**: Hi-C에서 epigenomic activity 예측. **핵심 성과 4 — Single-cell Hi-C 적용**: 단일세포 수준 3D genome 분석. **핵심**: HiC-Foundation 3D genome FM — Single-Cell Multi-Omics Industrializing Consolidating. **9월 17일 Scaling vs 오늘의 차별점**: 9/17이 **Li 12개 암종 56 LCPs spatial transcriptomics**를(Scaling)를, **DenAdel scFM dataset scaling plateau**를(Scaling)를 제시했다면, 오늘은 **Boya Ji CAPTAIN**으로 **scRNA + protein 382종 multimodal integration + zero-shot protein imputation**(Industrializing — multimodal FDAL 산업화突破口)를(new angle), **Wang X. HiC-Foundation**으로 **3D genome foundation model cross-species 적용**(Industrializing — 새로운 차원의 FDAL 산업화)을(new angle), **SCMBench**를 **Industrializing 한계로 재제시**한다. Scaling(9/17) → Single-Cell Multi-Omics FDAL Industrializing(9/18). 실무 함의: 단일세포 연구팀에서 Boya Ji et al.의 CAPTAIN을 참조하여 multimodal single-cell analysis strategy를 수립해야 한다. *출처: [Boya Ji CAPTAIN Multimodal FM Nature Communications 2026](https://consensus.app/papers/details/40361e55d4815c1dae3d5f6a95d4468a/), [Wang SCMBench Nature Communications 2026](https://consensus.app/papers/details/24b273d01c1f508c9a20a5a981ac2e3c/), [Wang HiC-Foundation Nature Methods 2026](https://consensus.app/papers/details/3b896f879f585bc4a16e4c799adbe311/)* *#SingleCell #MultiOmics #FoundationModel #BoyaJi #CAPTAIN #NatureCommunications #Multimodal #scRNA #Protein #382Proteins #4MCells #ZeroShot #Imputation #BatchHarmonization #Wang #SCMBench #FoundationModels #DomainSpecific #DMs #FMs #LightweightAdaptation #WangXiao #HiCFoundation #NatureMethods #HiC #3DGenome #Chromatin #Epigenomics #SingleCell #CrossSpecies #IndustrializingDay #Multimodal #Integration #BiomedicalAI #DailyReport* --- ### Post 7: Spatial Transcriptomics/Cancer Atlas — Spatial Omics TME Profiling + Pan-Cancer 12 Cancer Types 56 LCPs 🗺️ **[Spatial Transcriptomics/Cancer Atlas] Nguyen et al.으로 spatial omics TME profiling — ST/SP 통합 + cross-platform integration + AI/ML computational pipelines + precision cancer medicine 적용(Clinical & Translational Immunology 2026) + Li et al.으로 12개 암종 373 samples 56 LCPs + 13 recurrent niches + Niche_4 poor prognosis/immunotherapy resistance + Niche_11 better survival/-treatment response(Cell Reports Medicine 2026) + Zhang et al.으로 SCLC 600,000 cells + lymph node metastasis spatial transcriptomics + PIHs-1 independent survival predictor(Cell Reports Medicine 2026): Spatial Transcriptomics/Cancer Atlas Industrializing(산업화) 동시 확인** Spatial Transcriptomics/Cancer Atlas의**임상 적용 확대와 산업 생태계 형성(Industrializing)**이 출처에서 동시에 확인된다[13][14][15]. **Spatial Omics TME Profiling: Cross-Platform Integration + AI/ML[13]** H. Nguyen et al.(Clinical & Translational Immunology 2026)의 review는 spatial omics의 TME profiling 적용을 종합한다[13]. **핵심 성과 1 — ST + SP 통합**: spatial transcriptomics + spatial proteomics 통합. **핵심 성과 2 — AI/ML integration 강조**: cross-platform integration + computational pipelines. **핵심 성과 3 — Precision cancer medicine 적용**: 암精准医学 적용 확대. **Challenges**: cross-platform integration, data standardization, computational scalability. **핵심**: spatial omics TME profiling + AI/ML integration — Spatial Transcriptomics Industrializing Consolidating. **Pan-Cancer Spatial Transcriptomics: 12 Cancer Types 56 LCPs + Niches[14]** J. Li et al.(Cell Reports Medicine 2026)의 연구는 12개 암종의 spatial transcriptomic analysis를 수행한다[14]. **분석 규모**: 373 samples across 12 cancer types. **핵심 성과 1 — 56 LCPs 발견**: 56개 local cellular programs. **핵심 성과 2 — 13 recurrent niches**: 13개 반복 niches. **핵심 성과 3 — Niche_4 poor prognosis**: macrophage + tumor cell colocalization — poor prognosis + immunotherapy resistance. **핵심 성과 4 — Niche_11 better survival**: macrophage + immune cell colocalization — better survival + treatment response. **핵심**: 12 cancer types 56 LCPs + Niche_4/Niche_11 clinical outcomes — Spatial Transcriptomics Industrializing Consolidating. **SCLC Spatial Transcriptomics: 600,000 Cells + LNM + PIHs-1[15]** Z. Zhang et al.(Cell Reports Medicine 2026)의 연구는 SCLC의 공간적 종양 미세환경을 분석한다[15]. **분석 규모**: 600,000 cells across 105 primary and metastatic lymph node specimens from 75 SCLC patients. **핵심 성과 1 — 3개 LNM-enriched malignant subclusters**: distinct metabolic and angiogenic programs. **핵심 성과 2 — Vascular-immune crosstalk**: endothelial cells가 immune activation 조절. **핵심 성과 3 — PIHs-1 survival predictor**: pan-immune hotspot이 독립적 예후 인자. **핵심**: SCLC 600,000 cells + LNM spatial analysis + PIHs-1 — Spatial Transcriptomics Industrializing Consolidating. **9월 17일 Scaling vs 오늘의 차별점**: 9/17이 **Li 12개 암종 56 LCPs**를(Scaling)를, **Nguyen spatial omics TME review**를(Scaling)를 제시했다면, 오늘은 **Nguyen Clinical & Translational Immunology**으로 **ST/SP 통합 + AI/ML computational pipelines + precision cancer medicine 체계화**(Industrializing — 산업 적용 프레임워크)를(new angle), **Li Cell Reports Medicine**을 **Industrializing 임상 결과 해석**으로 재제시하고, **Zhang Cell Reports Medicine**을 **SCLC 600,000 cells + PIHs-1 independent predictor**(Industrializing — 독립적 예측 인자 발견)으로 추가 제시한다. Scaling(9/17) → Spatial Transcriptomics Industrializing(9/18). 실무 함의: 종양학 연구팀에서 Li et al.의 Niche_4/Niche_11 결과를 참조하여 immunotherapy response prediction strategy를 수립해야 한다. *출처: [Nguyen Spatial Omics TME Clinical & Translational Immunology 2026](https://consensus.app/papers/details/1b906e5abaaf5e789aaabde458127265/), [Li Pan-cancer Spatial Transcriptomics Cell Reports Medicine 2026](https://consensus.app/papers/details/f420ab985e1257e18352cac9e0c425cf/), [Zhang SCLC Spatial Transcriptomics Cell Reports Medicine 2026](https://consensus.app/papers/details/dc8b02ddbfcb574fb92b18cf8aed1117/)* *#SpatialTranscriptomics #CancerAtlas #Nguyen #ClinicalTranslationalImmunology #SpatialOmics #TME #ST #SP #Integration #CrossPlatform #AI #ML #PrecisionCancer #Li #CellReportsMedicine #PanCancer #12CancerTypes #LCP #Niche4 #Niche11 #PoorPrognosis #BetterSurvival #Immunotherapy #Resistance #Zhang #SCLC #SmallCellLungCancer #600000Cells #LymphNode #Metastasis #PIHs1 #SurvivalPredictor #IndustrializingDay #TME #SpatialMapping #BiomedicalAI #DailyReport* --- ### Post 8: 오늘의 요약 — Industrializing(산업화) Day 핵심 정리 🧬 **Industrializing(산업화) 핵심 정리** 오늘 9월 18일 Industrializing(산업화) Day의 핵심 메시지를 정리한다. **FDA 규제 구체화 — Feierman et al. AJHG 2026[1]** FDA 2026-02 plausible mechanism framework 공식 발표 + 7개 urea cycle disorders umbrella-of-umbrellas clinical trial FDA 공식 회의 완료. Ultra-rare genetic diseases를 위한 맞춤형 prime editing regulatory pathway 구체화. **CRISPR 신경계 질환 산업화 — Ji et al. Neuroprotection 2026[3]** Prime editing의 신경계 질환 적용 확대: split-AAV systems, lipid nanoparticles, engineered peptides 3가지 BBB penetration 전략으로 Rett syndrome, Fragile X, Dravet syndrome 등 적용 가능성 확대. **빅파마 AI Deals 산업화 — Lin et al. GEN Biotechnology 2026[4]** 2026년 Eli Lilly/Recursion/Regor/Novartis/AbbVie/Genentech 등 대형 AI Deals 급증. 생성형 AI, 단백질 설계, 합성 데이터, 약물 재창출 전領域에서 산업 투자 확대. **CAPTAIN Multimodal FDAL 산업화 — Boya Ji et al. Nature Communications 2026[10]** scRNA + surface protein 382종 co-assay 4M cells 통합 학습 multimodal FDAL. Zero-shot protein imputation + batch harmonization으로 산업 적용 가능성 확대. **Spatial Omics TME 산업화 — Nguyen et al. Clinical & Translational Immunology 2026[13]** Spatial transcriptomics + spatial proteomics 통합 + AI/ML computational pipelines + precision cancer medicine 체계적 적용. Cross-platform integration과 computational scalability 도전과제 확인. **Pan-Cancer Spatial 산업화 — Li et al. Cell Reports Medicine 2026[14]** 12개 암종 373 samples에서 56 LCPs + 13 niches 발견. Niche_4(poor prognosis/immunotherapy resistance)와 Niche_11(better survival/treatment response)으로 임상 예후 예측 가능성 확인. **AlphaFold 산업화 한계 — Singh et al. Current Opinion Structural Biology 2026[7]** AlphaFold-like models의 protein-ligand data gap 체계적 분석. PDB 50년 축적에도 실제 약물 발견 태스크를 위한 dataset 확대 필요. **단백질 AI 산업화 적용 — Kinde et al. Results in Engineering 2026[8]** AlphaFold drug discovery-acceleration + disease mechanism elucidation + vaccine design 적용 종합. Hybrid methods로 disorder/동적 구조 한계 극복. *출처: [Feierman AJHG](https://consensus.app/papers/details/c10e0f99f20b517e8bb3b5ae4b666dcc/), [Ji Neuroprotection](https://consensus.app/papers/details/6f2f6891edcd524b9e54932910f51d1d/), [Lin GEN Biotechnology](https://consensus.app/papers/details/bc6e9ea3ec2e5025af707131d2fa0ca7/), [Boya Ji Nature Communications](https://consensus.app/papers/details/40361e55d4815c1dae3d5f6a95d4468a/), [Nguyen Clinical & Translational Immunology](https://consensus.app/papers/details/1b906e5abaaf5e789aaabde458127265/), [Li Cell Reports Medicine](https://consensus.app/papers/details/f420ab985e1257e18352cac9e0c425cf/), [Singh Current Opinion](https://consensus.app/papers/details/81a3128ae1615cfeb1bd6544d3ad2f1b/), [Kinde Results in Engineering](https://consensus.app/papers/details/f459a7af7e615e27bfe6bd6e14625fea/)* *#IndustrializingDay #Industrializing #FDA #PlausibleMechanism #PrimeEditing #Neuropsychiatric #BBB #BigPharma #AI #Deals #CAPTAIN #Multimodal #FoundationModel #SpatialOmics #TME #PanCancer #LCP #Niche #AlphaFold #ProteinAI #DrugDiscovery #Summary #Synthesizing #Scaling #Industrializing #ClinicalTranslation #RegulatoryFramework #BiomedicalAI #DailyReport* --- ## Sources (1차 출처 12개 이상) [1] [Feierman et al. — FDA Plausible Mechanism Framework, AJHG 2026](https://consensus.app/papers/details/c10e0f99f20b517e8bb3b5ae4b666dcc/) [2] [Oo et al. — FDA Gene Therapy Approvals 38 CGTs, J Clinical Pharmacology 2026](https://consensus.app/papers/details/181658e93c825ea581a0664845a98d12/) [3] [Ji et al. — Prime Editing Neuropsychiatric Disorders, Neuroprotection 2026](https://consensus.app/papers/details/6f2f6891edcd524b9e54932910f51d1d/) [4] [Lin et al. — Pharma Bets Big on AI 2026 Deals, GEN Biotechnology 2026](https://consensus.app/papers/details/bc6e9ea3ec2e5025af707131d2fa0ca7/) [5] [Liu et al. — Multi-Omics AI Drug Discovery, Signal Transduction Targeted Therapy 2026](https://consensus.app/papers/details/33ddb4ae99c05f869b6de8bd3c432a98/) [6] [Seyhan et al. — AI Drug Discovery Development, Critical Reviews Oncology Hematology 2026](https://consensus.app/papers/details/0e6b685fd2be56fb8a814115873a73d5/) [7] [Singh et al. — AlphaFold Protein-Ligand Data Gap, Current Opinion Structural Biology 2026](https://consensus.app/papers/details/81a3128ae1615cfeb1bd6544d3ad2f1b/) [8] [Kinde et al. — AlphaFold Applications, Results in Engineering 2026](https://consensus.app/papers/details/f459a7af7e615e27bfe6bd6e14625fea/) [9] [Yin et al. — AlphaFold Comprehensive Review, Frontiers Molecular Biosciences 2026](https://consensus.app/papers/details/880e72fce35255c4887811c76849c03a/) [10] [Boya Ji et al. — CAPTAIN Multimodal FM, Nature Communications 2026](https://consensus.app/papers/details/40361e55d4815c1dae3d5f6a95d4468a/) [11] [Wang et al. — SCMBench, Nature Communications 2026](https://consensus.app/papers/details/24b273d01c1f508c9a20a5a981ac2e3c/) [12] [Wang X. et al. — HiC-Foundation, Nature Methods 2026](https://consensus.app/papers/details/3b896f879f585bc4a16e4c799adbe311/) [13] [Nguyen et al. — Spatial Omics TME Profiling, Clinical & Translational Immunology 2026](https://consensus.app/papers/details/1b906e5abaaf5e789aaabde458127265/) [14] [Li et al. — Pan-cancer Spatial Transcriptomics 12 Cancer Types, Cell Reports Medicine 2026](https://consensus.app/papers/details/f420ab985e1257e18352cac9e0c425cf/) [15] [Zhang et al. — SCLC Spatial Transcriptomics, Cell Reports Medicine 2026](https://consensus.app/papers/details/dc8b02ddbfcb574fb92b18cf8aed1117/)
Research Pulse·2026-09-18
Research Pulse — 2026-09-18
28 journals × 7 topics · fibrosis · OXPHOS · ferroptosis · sarcopenia · senescence
Raw data + scoring: Daily Tech Digest (separate feed)
Request a Paid Brief